Why is it so difficult to develop drugs for children with cancer? What can be done to stimlate investments in the pediatric oncology space? These questions are central to a new study published by MIT Sloan researchers that explores new business models for funding drug development to treat pediatric cancers.
The presentation sumamrizes the key findings of the study & talks about the challenges of developing drugs for pediatric cancer–and offers a potential solution. The study finds that a collaborative investment structure involving backing from the private sector, government, and philanthropic organizations holds the greatest promise for new drug discovery in pediatric oncology.